Page last updated: 2024-08-21

fluorobenzenes and Pulmonary Hypertension

fluorobenzenes has been researched along with Pulmonary Hypertension in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (33.33)29.6817
2010's6 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jasińska-Stroschein, M; Orszulak-Michalak, D; Owczarek, J; Wesołowska, A1
Adachi, O; Fukushige, S; Horii, A; Kawamoto, S; Matsuo, S; Saiki, Y1
Maeda, K; Ruel, M1
Barreto, AC; Cícero, C; Lopes, AA; Maeda, NY; Soares, RP1
Andresen, BT; Dellsperger, KC; DeMarco, VG; Ferrario, CM; Gutweiler, AA; Habibi, J; Johnson, MS; Ma, L; Schneider, RI; Sowers, JR; Whaley-Connell, AT1
Guan, RJ; Li, XL; Wu, ZY; Xu, QH1
Dai, G; Ma, P; Pei, Y; Wang, X; Xu, Q; Yan, L; Zhang, W; Zhang, X; Zheng, P1
Guan, RJ; Li, JJ; Li, XL1
Ku, DD; Sun, X1

Trials

1 trial(s) available for fluorobenzenes and Pulmonary Hypertension

ArticleYear
Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertension: a placebo-controlled study.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2008, Volume: 41, Issue:8

    Topics: Adolescent; Adult; Biomarkers; Case-Control Studies; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Female; Fluorobenzenes; Heart Defects, Congenital; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Male; Middle Aged; P-Selectin; Pyrimidines; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides; Tissue Plasminogen Activator; von Willebrand Factor; Young Adult

2008

Other Studies

8 other study(ies) available for fluorobenzenes and Pulmonary Hypertension

ArticleYear
Rosuvastatin, sildenafil and their combination in monocrotaline-induced pulmonary hypertension in rat.
    Acta pharmaceutica (Zagreb, Croatia), 2014, Volume: 64, Issue:3

    Topics: Animals; Antihypertensive Agents; Arterial Pressure; Biomarkers; Cholesterol, HDL; Disease Models, Animal; Drug Therapy, Combination; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Natriuretic Peptide, Brain; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Artery; Purines; Pyrimidines; Rats, Wistar; Rosuvastatin Calcium; Sildenafil Citrate; Sulfonamides; Time Factors; Vascular Endothelial Growth Factor A; Vascular Remodeling; Vasodilator Agents; Ventricular Function, Right; Ventricular Pressure

2014
Single-dose rosuvastatin ameliorates lung ischemia-reperfusion injury via upregulation of endothelial nitric oxide synthase and inhibition of macrophage infiltration in rats with pulmonary hypertension.
    The Journal of thoracic and cardiovascular surgery, 2015, Volume: 149, Issue:3

    Topics: Animals; Anti-Inflammatory Agents; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Disease Models, Animal; Endothelium, Vascular; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Lung; Lung Injury; Macrophages; Male; Mevalonic Acid; Monocrotaline; Nitric Oxide Synthase Type III; Oxygen; Phosphorylation; Pulmonary Edema; Pyrimidines; Rats, Sprague-Dawley; Reperfusion Injury; Rosuvastatin Calcium; Sulfonamides; Up-Regulation

2015
Prevention of ischemia-reperfusion injury in cardiac surgery: therapeutic strategies targeting signaling pathways.
    The Journal of thoracic and cardiovascular surgery, 2015, Volume: 149, Issue:3

    Topics: Animals; Anti-Inflammatory Agents; Endothelium, Vascular; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Lung; Lung Injury; Macrophages; Male; Nitric Oxide Synthase Type III; Pyrimidines; Reperfusion Injury; Rosuvastatin Calcium; Sulfonamides

2015
Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat.
    American journal of physiology. Heart and circulatory physiology, 2009, Volume: 297, Issue:3

    Topics: Angiotensinogen; Animals; Fluorobenzenes; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Left Ventricular; Hypertrophy, Right Ventricular; Magnetic Resonance Imaging; Male; Membrane Glycoproteins; NADPH Oxidase 2; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Peptidyl-Dipeptidase A; Pulmonary Artery; Pyrimidines; rac1 GTP-Binding Protein; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptor, Angiotensin, Type 1; Rosuvastatin Calcium; Sulfonamides; Ventricular Function, Left; Ventricular Function, Right

2009
[Effects of rosuvastatin on monocrotaline-induced pulmonary artery hypertension in rats].
    Zhonghua xin xue guan bing za zhi, 2011, Volume: 39, Issue:3

    Topics: Animals; Cell Proliferation; Endothelial Cells; Familial Primary Pulmonary Hypertension; Fluorobenzenes; Hypertension, Pulmonary; Hypolipidemic Agents; Male; Monocrotaline; Myocytes, Smooth Muscle; Nitric Oxide Synthase Type III; Proliferating Cell Nuclear Antigen; Pyrimidines; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; Rosuvastatin Calcium; Sulfonamides

2011
Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism.
    European journal of pharmacology, 2011, Volume: 666, Issue:1-3

    Topics: Amidohydrolases; Animals; Arginine; Biomarkers; Body Weight; Fluorobenzenes; Gene Expression Regulation, Enzymologic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Heart; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Nitric Oxide Synthase Type III; Organ Size; Protein-Arginine N-Methyltransferases; Proto-Oncogene Proteins c-akt; Pyrimidines; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Signal Transduction; Sulfonamides; Ventricular Dysfunction, Right

2011
Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin.
    Journal of cardiovascular pharmacology, 2012, Volume: 60, Issue:2

    Topics: Animals; Antihypertensive Agents; Arterial Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Familial Primary Pulmonary Hypertension; Fluorobenzenes; Gene Expression Regulation, Enzymologic; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Nitric Oxide Synthase Type III; Proliferating Cell Nuclear Antigen; Pulmonary Artery; Pyrimidines; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; RNA, Messenger; Rosuvastatin Calcium; Sulfonamides; Time Factors

2012
Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats.
    American journal of physiology. Heart and circulatory physiology, 2008, Volume: 294, Issue:2

    Topics: Animals; Blood Pressure; Blotting, Western; Body Weight; Coronary Disease; Endothelium, Vascular; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Nitric Oxide; Organ Size; Poisons; Pyrimidines; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Sulfonamides

2008